Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
16
×
Tags
boston
16
×
boston blog main
boston top stories
life sciences
national blog main
national top stories
16
×
san francisco blog main
16
×
biotech
san francisco top stories
new york blog main
clinical trials
fda
deals
new york top stories
san diego blog main
startups
vc
indiana blog main
rna interference
roche
alnylam pharmaceuticals
eli lilly
genentech
indiana top stories
medical devices
san diego top stories
venture capital
wisconsin blog main
akcea therapeutics
avapritinib
barry greene
blueprint medicines
boulder/denver blog main
cancer
craig mello
dan ollendorf
detroit blog main
dna
drugs
feng zhang
What
medicines
drug
fda
medicine
startup
therapeutics
ago
biotechs
gene
ipos
rna
science
alnylam
approach
approval
blueprint
called
cancer
crispr
data
diseases
drugs
editing
fix
genetic
gets
interference
ipo
leads
life
long
million
morning
muscle
patients
research
ret
rnai
roche
therapy
Language
unset
Current search:
photo
×
boston
×
" national top stories "
×
" san francisco blog main "
×
@xconomy.com
3 years ago
Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
5 years ago
CRISPR Diagnostic Race Heats Up as Sherlock Bio Launches With $35M
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
5 years ago
Andreessen Leads $300M Bet on Devoted Health’s Senior Care Approach
@xconomy.com
5 years ago
Six Life Science Firms Close Q3 with an IPO, More Are on the Way
@xconomy.com
5 years ago
In Boston’s Shadow, Rhode Island Fights for Life Science Jobs, Respect
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com
5 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine
@xconomy.com
6 years ago
CAR-T’s Launch, Payers vs. Gene Therapy & Photos From “What’s Hot”
@xconomy.com
6 years ago
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M